Display options
Cite
Tamgue O, Lei M. Triptolide Promotes Senescence of Prostate Cancer Cells Through Histone Methylation and Heterochromatin Formation. Asian Pac J Cancer Prev. 2017;18(9):2519-2526doi: 10.22034/APJCP.2017.18.9.2519.
Tamgue, O., & Lei, M. (2017). Triptolide Promotes Senescence of Prostate Cancer Cells Through Histone Methylation and Heterochromatin Formation. Asian Pacific journal of cancer prevention : APJCP, 18(9), 2519-2526. https://doi.org/10.22034/APJCP.2017.18.9.2519
Tamgue, Ousman, and Lei, Ming. "Triptolide Promotes Senescence of Prostate Cancer Cells Through Histone Methylation and Heterochromatin Formation." Asian Pacific journal of cancer prevention : APJCP vol. 18,9 (2017): 2519-2526. doi: https://doi.org/10.22034/APJCP.2017.18.9.2519
Tamgue O, Lei M. Triptolide Promotes Senescence of Prostate Cancer Cells Through Histone Methylation and Heterochromatin Formation. Asian Pac J Cancer Prev. 2017 Sep 27;18(9):2519-2526. doi: 10.22034/APJCP.2017.18.9.2519. PMID: 28952292; PMCID: PMC5720660.
Copy Download .nbib Format: NLM
Share it on

Asian Pac J Cancer Prev. 2017 Sep 27;18(9):2519-2526. doi: 10.22034/APJCP.2017.18.9.2519.

Triptolide Promotes Senescence of Prostate Cancer Cells Through Histone Methylation and Heterochromatin Formation.

Asian Pacific journal of cancer prevention : APJCP

Ousman Tamgue, Ming Lei

Affiliations

  1. University of Cape Town, Institute of Infectious Diseases and Molecular Medicine (IDM), Division of Immunology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
  2. College of Life Science, Northwest A&F University, 3 Taicheng Road, Yangling, 712100, China. Email: [email protected]

PMID: 28952292 PMCID: PMC5720660 DOI: 10.22034/APJCP.2017.18.9.2519

Abstract

Background: Triptolide is a medicinal herb-derived diterpene triepoxide with potent anti-tumor activity, mainly ,correlated with its ability to inhibit and inactivate subunits of RNA polymerase II, thereby suppressing global gene transcription. Epigenetic imbalance including histone methylation are well known to play important roles in prostate cancer (PCa) onset and progression. The goal of this study was to investigate whether triptolide might exert anti-PCa influence by reshaping the histone methylation landscape. Methods: Triptolide-treated PCa cell lines were analyzed by RT-qPCR and western blotting for expression of histone demethylases and associated markers. Detection of senescence was achieved using senescence associated β-galactosidase staining and analyses of apoptosis and cell cycle were performed by flow cytometry. Senescence–associated heterochromatin foci were detected by immunofluorescence while chromatin immunoprecipitation associated with qPCR (CHIP-qPCR) was applied to assess accumulation of histone markers on promoters of target genes. Cell viability was determined using the CCK-8 assay. Results: We found triptolide to enhance H3K27me3 levels by down-regulating JMJD3 and UTX and also H3K9me3 through up-regulation of SUV39H1. Furthermore, it up-regulated expression of HP1α. Thereby, heterochromatin formation and deposition on promoters of E2F1-target genes was promoted, correlating with suppression of gene transcription, decreased cell viability and induction of a senescence-like phenotype in PCa cells. Conclusions: Our results indicate that triptolide exerts anti-tumor effects including PCa cell senescence at least partially through increasing the levels of repressive histone H3 methylation and formation of a repressive chromatin state in PCa cells. Further studies of its potential as an epigenetic anti-PCa drug appear warranted.

Creative Commons Attribution License

Keywords: Triptolide; prostate cancer; senescence; Histone; Methylation; Heterochromatin

References

  1. Cancer Res. 2012 Oct 15;72(20):5363-73 - PubMed
  2. Eur J Pharmacol. 2010 Nov 10;646(1-3):1-11 - PubMed
  3. Nat Med. 2016 Feb;22(2):128-34 - PubMed
  4. EMBO J. 2004 Feb 11;23(3):605-15 - PubMed
  5. Cell. 2003 Jun 13;113(6):703-16 - PubMed
  6. Mol Cell. 2005 Jul 22;19(2):147-57 - PubMed
  7. Mol Cell Biol. 2000 May;20(10):3728-41 - PubMed
  8. Asian Pac J Cancer Prev. 2013;14 (10 ):5663-9 - PubMed
  9. Oncol Rep. 2009 Dec;22(6):1397-401 - PubMed
  10. Oncol Rep. 2011 Nov;26(5):1315-21 - PubMed
  11. Genomics. 2014 Feb-Mar;103(2-3):204-10 - PubMed
  12. Cell. 2007 Feb 23;128(4):693-705 - PubMed
  13. Nature. 2001 Mar 1;410(6824):116-20 - PubMed
  14. Curr Opin Cell Biol. 2013 Apr;25(2):184-9 - PubMed
  15. PLoS One. 2011;6(9):e23993 - PubMed
  16. Biochim Biophys Acta. 2009 Sep;1790(9):863-8 - PubMed
  17. Nat Chem Biol. 2011 Mar;7(3):182-8 - PubMed
  18. Nat Struct Mol Biol. 2007 Nov;14(11):1008-16 - PubMed
  19. Mol Cancer Ther. 2009 Oct;8(10 ):2780-90 - PubMed
  20. Cancer Res. 2007 Oct 1;67(19):9407-16 - PubMed
  21. Science. 2001 Aug 10;293(5532):1074-80 - PubMed
  22. J Am Chem Soc. 1972 Oct 4;94(20):7194-5 - PubMed
  23. PLoS One. 2012;7(5):e37693 - PubMed
  24. Cold Spring Harb Symp Quant Biol. 2010;75:43-9 - PubMed
  25. Nat Chem Biol. 2014 Aug;10(8):623-5 - PubMed
  26. Semin Cancer Biol. 2004 Dec;14(6):427-32 - PubMed

Publication Types